WHITE PAPER
Why Are Clinical Development Success Rates Falling?
Is biopharma continuing to become less successful in clinical development? What are the underlying reasons dragging success rates down and can they be mitigated? What does this mean for R&D productivity and the return on investment on pipeline spend?